Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung08: datopotamab deruxtecan plus pembrolizumab versus pembrolizumab alone in first-line PD-L1-high advanced NSCLC
NL-OMON55935Phase 3Not yet recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Dato-DXd + pembrolizumab with Pembrolizumab alone (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
datopotamab deruxtecanpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON55935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55935.